BioReliance Licenses B-CLEAR Technology from Qualyst Transporter Solutions for Drug Transporter Studies
BioReliance, Sigma-Aldrich Corporation's biologics and early-development services business under SAFC Commercial, has announced a non-exclusive license agreement with Qualyst Transporter Solutions (QTS) for its proprietary B-CLEAR technology. Used in conjunction with BioReliance technologies, B-CLEAR enables researchers to assess drug disposition and drug interactions within complex, whole-cell liver systems.
When applied to properly functioning hepatic cells, B-CLEAR opens the bile pockets (analogous to bile canaliculi in vivo), allowing material that has been transported from inside the cell into the bile pocket to be measured. The efflux measurements can then facilitate evaluation of biliary clearance, transporter interactions and intracellular concentration.
Until now, the study of the individual role of a transporter in primary hepatocytes and HepaRG cells, which express all of the hepatic transporters, was very difficult. However, by using Sigma-Aldrich CompoZr Zinc Finger Nuclease (ZFN) technology, HepaRG transporter knockout cell lines have been created empowering more accurate research investigations of liver transporters. The B-CLEAR technology enables effective measurement of uptake and efflux into the bile pocket, and the overall integrated effect of transporters and metabolism can also be evaluated.
“The ability to accurately predict drug transporter interactions in the liver is a critical part of developing safer and more efficacious therapies,” said Paul Brooks, Head of Discovery Research Services at Sigma-Aldrich. “We have licensed the B-CLEAR technology to offer a more complete support service for drug transporter assessment, which is in line with BioReliance’s drive to deliver the most innovative advances in in vitro ADME/Tox studies to address customers’ most pressing needs.”
“B-CLEAR technology exclusively allows users to measure compound in the bile pocket, and is the first technology of its kind to enable measuring of physiologic intracellular concentrations. Whether a user is interested in uptake transporter knockouts or efflux transporter knockouts, measuring changes in intracellular concentration is the perfect readout to understand their effects,” said Dr Christopher Black, CEO for Qualyst Transporter Solutions. “We are thrilled to make this licensing agreement with Sigma-Aldrich and BioReliance, and look forward to seeing its positive impact on the pharmaceutical industry.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance